Robert W. Baird Cuts Agenus (NASDAQ:AGEN) Price Target to $3.00

Agenus (NASDAQ:AGEN) had its price target reduced by equities researchers at Robert W. Baird from $6.00 to $3.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Robert W. Baird’s target price would indicate a potential upside of 46.34% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Agenus presently has a consensus rating of “Hold” and a consensus price target of $8.75.

Agenus Stock Performance

Shares of AGEN opened at $2.05 on Wednesday. The company has a market capitalization of $48.09 million, a price-to-earnings ratio of -0.18 and a beta of 1.23. Agenus has a 1 year low of $1.93 and a 1 year high of $19.69. The company’s 50 day simple moving average is $3.24 and its 200 day simple moving average is $3.85.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, beating the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. Equities analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Trading of Agenus

A number of institutional investors have recently modified their holdings of AGEN. B. Riley Financial Inc. purchased a new position in Agenus in the fourth quarter valued at approximately $2,074,000. Gilead Sciences Inc. acquired a new stake in shares of Agenus in the fourth quarter worth $635,000. Walleye Capital LLC purchased a new position in shares of Agenus in the 3rd quarter valued at $1,003,000. Jane Street Group LLC raised its stake in shares of Agenus by 97.6% in the 4th quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after acquiring an additional 52,215 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Agenus by 538.4% during the 4th quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 51,566 shares in the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.